S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer

Recruiting in Palo Alto (17 mi)

+203 other locations

Overseen byAlfred I. Neugut, MD, PhD

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Southwest Oncology Group

No Placebo Group

Trial Summary

What is the purpose of this trial?

RATIONALE: Measuring how text-message affects treatment compliance in women with breast cancer may help doctors plan the best treatment. PURPOSE: This randomized trial studies how well text-message works in reducing early discontinuation of aromatase inhibitor therapy in patients with early-stage breast cancer who underwent breast surgery.

Research Team

Alfred I. Neugut, MD, PhD

Principal Investigator

Herbert Irving Comprehensive Cancer Center

Eligibility Criteria

Inclusion Criteria

Patients must be women with a diagnosis of histologically confirmed, primary invasive, hormone-sensitive (estrogen receptor-positive [ER]/progesterone receptor [PR]-positive) adenocarcinoma of the breast (Stage I, II or III) with no evidence of recurrent or metastatic disease (M0)

Patients must have a mobile phone that can receive text messages and must currently use or be willing to learn to use text messaging

≥ 12 months since the last menstrual period

See 7 more

Treatment Details

Interventions

Text message reminder (Behavioral Intervention)

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: Text message reminderExperimental Treatment1 Intervention

Patients undergo a text message education checklist involving confirmation of cellular telephone capability to receive text messages, how to retrieve and read messages, including a confirmation evaluation, at baseline and at any time a patient obtains a new cellular telephone. Patients then receive a text message twice a week at 8 o'clock in the morning (for each time zone) for up to 3 years. Additionally, patients receive standard follow-up care.

Group II: No text message reminderActive Control1 Intervention

Patients receive standard follow-up care.